<DOC>
	<DOCNO>NCT03059615</DOCNO>
	<brief_summary>This Phase 2a , Open-label , one arm study eligible patient treat IV Nerofe , three time week 28 day cycle ( 12 cycle ) . Evaluation include safety procedure , blood level study drug certain time point , immune system response test check mechanism drug action .</brief_summary>
	<brief_title>A Phase 2a , Open-Label , Dose-Escalation Study IV Nerofe Subjects With AML MDS</brief_title>
	<detailed_description>Nerofe first-in-class hormone peptide cancer suppressive property . It work three mechanisms action . The purpose research study Nerofe 's effect patient diagnose AML MDS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Males females &gt; 18 year age 2 . Either : AML patient , candidate aggressive therapy and/or stem cell transplant ( usually elderly patient ) , Intermediate2 high prognostic risk MDS patient ( accord IPSS classification ) , resistant relapse follow least 1 course hypomethylation therapy 3 . Antitumor ( case antiMDS antileukemic ) effect measure accord IWG criterion 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 5 . Acceptable clinical laboratory value screen 6 . Pretreatment baseline measure cytopenias average least 2 measurement ( influenced transfusion , i.e. , RBC transfusion least 1 week platelet transfusion least 3 day ) least 1 week prior therapy 7 . Negative serum β hCG test woman childbearing potential ( defined woman ≤ 50 year age history amenorrhea ≤ 12 month prior study entry ) 8 . Willing able provide write Informed Consent comply requirement study 9 . Willing able provide write acceptance follow period , bone marrow examination perform , cytogenetics . Bone marrow examination perform initiation , follow 2 , 3 , 6 , 12 month 1 . Any chemotherapy , immunomodulatory drug therapy , antineoplastic hormonal therapy ( unless dose stable 3 month prior Baseline remain stable trial ) , immunosuppressive therapy , prednisone &gt; 20 mg/day equivalent corticosteroid , erythropoietin within 14 day prior initiation study drug 2 . Erythroid stimulate agent allow within 8 week prior study initiation 3 . Presence acute toxicity prior chemotherapy , exception alopecia peripheral neuropathy , resolve ≤ Grade 1 , determine NCI CTCAE v 4.0 4 . Receipt &gt; 1 prior regimen genotoxic therapy 5 . Receipt &gt; 1 blood transfusion per month 6 . Life expectancy &lt; 12 week 7 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndromerelated illness 8 . Known active hepatitis B C active liver disease ( malignancy ) 9 . Active infection require systemic therapy 10 . Insulinrequiring diabetes mellitus 11 . History follow within 12 month prior initiation study drug : Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , unstable angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism 12 . Uncontrolled arterial hypertension , antihypertensive drug whose type dose change within 3 month prior screen whose dose anticipated change within cycle 1 13 . Uncontrolled decompensated cardiac dysrhythmias require active treatment , persistent prolongation QTc ( Fridericia ) interval &gt; 450 msec male &gt; 470 msec female 14 . Malignancies reason exclusion active last year require antitumor treatment . Skin nonmelanomatous tumor thyroid carcinoma include 15 . Use investigational agent within minimum 3 week 5 halflives initiation study drug 16 . Pregnant lactate female 17 . Women childbearing potential , unless agree use dual contraceptive method , opinion Principal Investigator , effective adequate patient 's circumstance study drug 3 month afterward 18 . Men partner woman childbearing potential , unless agree use effective , dual contraceptive method ( i.e. , condom , female partner use oral , injectable , barrier method ) study drug 3 month afterward 19 . Any severe , acute , chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere informed consent process and/or compliance requirement study , may interfere interpretation study result , investigator 's opinion , would make patient inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>